We commonly use BPC-157 as part of our treatment for the following conditions: Chronic gastrointestinal (GI) issues, including colitis, Crohns disease, irritable bowel disease (IBD), gastritis, ulcers, and esophagitis
For maintenance, it is common to have monthly therapy of 100-200 mcg
Moreover, Exendin-4 significantly increases A-induced decrease in mitochondrial function, integrity and respiratory control rate in all brain regions (189)
As polymeric, inorganic, and lipid-based nanoparticles are designed using more accurate methods, they can be optimized for more personalized medication administration, ushering in the era of precision medicine (Fig
PMID 27592340